BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hepatitis Delta readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Hepatitis Delta\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07128550-9829@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tobevibart (VIR-3434): Phase 3 readout est. (NCT07128550)
DESCRIPTION:Tobevibart (VIR-3434)\, phase 3\, Chronic Hepatitis Delta.\nStu
 dy: A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic 
 HDV Infection Not Virologically Suppressed With Bulevirtide\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tobevibart-vir-3434#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07128550
URL:https://assetmemo.bio/drug/tobevibart-vir-3434#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07499544-9888@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280912
DTEND;VALUE=DATE:20280913
SUMMARY:Libevitug (HH-003): Phase 3 readout est. (NCT07499544)
DESCRIPTION:Libevitug (HH-003)\, phase 3\, Chronic Hepatitis Delta.\nStudy:
  A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Par
 ticipants With Chronic HDV Infection (D-clear Study)\nEstimated primary co
 mpletion: 12 September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/libevitug-hh-003#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07499544
URL:https://assetmemo.bio/drug/libevitug-hh-003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07142811-9829@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Tobevibart (VIR-3434): Phase 2 readout est. (NCT07142811)
DESCRIPTION:Tobevibart (VIR-3434)\, phase 2\, Chronic Hepatitis Delta.\nStu
 dy: A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic
  HDV Infection\nEstimated primary completion: March 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tobevibart-vir-3434#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07142811
URL:https://assetmemo.bio/drug/tobevibart-vir-3434#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
